Table 1 summarizes the studies performed with anti-L1CAM monoclonal antibodies in preclinical settings. The data available so far also indicate an acceptable toxicity profile, although this aspect should be investigated in much greater detail in view of the possible clinical application. Of note, also the liposome encapsulation of anti-L1CAM siRNA provided a therapeutic tool that suppressed the growth and metastasis of prostate cancer [99]. Here, L1CAM is linked to prostate cancer.